Related Experiment Videos
Cardiac arrhythmias: the role of pharmacologic intervention
1Department of Pediatrics, UCLA School of Medicine.
Insights
Selecting antiarrhythmic drugs for children requires understanding electrophysiology and pharmacokinetics to balance benefits and risks. This guide aids in developing management strategies for pediatric arrhythmias.
Area of Science:
- Pediatric Cardiology
- Clinical Pharmacology
- Cardiac Electrophysiology
Background:
- The increasing availability of antiarrhythmic drugs for pediatric use necessitates careful selection.
- Current treatment selection often relies on electrophysiologic and pharmacokinetic principles.
- Balancing the benefit-to-side effect ratio is crucial for effective pediatric arrhythmia management.
Purpose of the Study:
- To promote understanding of how anatomic, electrophysiologic, and developmental pharmacology principles guide pediatric antiarrhythmic therapy.
- To provide a guideline for developing management strategies for individual pediatric patients with arrhythmias.
- To offer a framework for incorporating new antiarrhythmic agents into clinical practice.
Main Methods:
- Review of existing literature on pediatric arrhythmias and antiarrhythmic drug therapy.
- Emphasis on the integration of electrophysiologic principles and pharmacokinetic data.
- Consideration of developmental pharmacology relevant to pediatric patients.
Main Results:
- The study highlights the importance of integrating anatomic considerations, basic electrophysiology, and developmental pharmacology in therapy selection.
- It acknowledges that many cited studies are investigational and not all applications are FDA-approved for pediatric use in the US.
- The information serves as a guideline for managing pediatric arrhythmias.
Conclusions:
- Effective antiarrhythmic drug selection in children depends on a deep understanding of underlying principles.
- Therapeutic strategies should be individualized based on patient-specific factors and emerging pharmacological data.
- The principles discussed provide a foundation for adapting to new antiarrhythmic agents as they become available for pediatric use.
Abstract:
The growing menu of drugs used to treat arrhythmias in children enhances the importance of antiarrhythmic selection based on the application of underlying electrophysiologic and pharmacokinetic principles, as well as a reduction of the side effect to benefit ratio. No attempt has been made in this report to discuss the diagnosis of arrhythmias in children, nor is the list of agents we discuss all-encompassing. Rather, the major thrust has been to promote an understanding of the important relationship between anatomic considerations, basic electrophysiology, and developmental pharmacology in directing therapy. We wish to emphasize that many of the studies quoted in this report are investigational, and that not all of the applications listed in the text and tables are approved for use in pediatric patients in the United States. Nevertheless, the information may serve as a guideline to developing management strategies for the individual child with an arrhythmia. Given the number of new antiarrhythmic agents under development, it would be no surprise if, in a few years, a paper such as this one discussed several new drugs we have not mentioned. We hope that the principles we have outlined will serve as a framework for incorporating these new agents into clinical practice as they become available.